DUNCAN MCLAREN
Mr. Mclaren has an eighteen-year proven track record of creating and scaling technology and health businesses. Among those accomplishments, in 2014 he co-founded MyGiHealth; a platform that has revolutionized the way that doctors and patients communicate to facilitate better health outcomes. Mr. Mclaren has hands on experience accelerating the identification and randomization of patients into clinical trials. Mr. Mclaren has been a board member of Digestive Health Associates since 2017, an organization dedicated to improved gastrointestinal health.
Mr. McLaren holds a BSc in Oceanography from the University of Southampton and a MBA in Business Administration from San Diego State University.
BILL ALBRO
Mr. Albro is a respected pharmaceutical executive with over 15 years in the industry. He brings domain expertise to the table with his background as a formulation scientist. In addition, Mr. Albro has extensive experience managing inter-disciplinary drug discovery teams. Most recently, Mr. Albro has served as a Strategic Leader at companies such as ThermoFisher Scientific and Merck KGA.
Mr. Albro has a Bachelors of Science in Biology from Fairfield University and a MBA in Management from Rensselaer Polytechnic Institute.
ADVISORY BOARD
JILL S. SIMONIAN, PHARMD
Dr. Jill S. Simonian received her PharmD from the University of California, San Francisco and built her expertise during a 25-year career at the Veterans Administration Hospital in La Jolla, focusing on direct patient care and Adverse Drug Reaction reporting. More recently, she switched her attention towards the emerging cannabis sector where Dr. Simonian focused on the pharmacology and therapeutic use of cannabis, advocating for evidence-based education within the healthcare community. She lectures nationally on cannabis topics and teaches a course on "Cannabinoid Pharmacology and Therapeutics" at UC San Diego and UC Irvine. Furthermore, she’s a founding member of the Pharmacists’ Cannabis Coalition of California, bridging the gap between healthcare and cannabis for enhanced patient health and safety.
ROGER COE
Mr. Coe is President of Briggs Capital Advisors and has over 35 years of capital markets experience as an executive with leading investment banking firms as well as privately advising on numerous family office accounts. Mr. Coe has participated in hundreds of principal transactions and has managed numerous venture capital, institutional and banking relationships on behalf of dozens of CEO. Over a 25-year period. Mr. Coe was primary financial advisor to one of the pioneers of the venture capital industry in connection with day to day management and trading responsibilities for a diversified securities portfolio aggregating more than $400 million. Mr. Coe’s sales experience spans multiple industries including technology, consumer, biotech and healthcare. Mr.Coe was Managing Director and head of the Corporate Executive Services for CIBC/Oppenheimer in Boston.
DR RAJIV SHARMA
Dr. Rajiv Sharma attended medical school at Dayanand Medical College, Punjab, India. He received his Internal Medicine training from Loma Linda University, Loma Linda, California and received his Gastroenterology Fellowship training from University of Rochester, Rochester, New York. Dr. Sharma trained under the mentorship of Dr. Richard G. Farmer, who is world renowned for his work on Inflammatory Bowel Disease.
Dr. Sharma’s special interests include GERD, NERD, Inflammatory Bowel Disease (Crohn’s & Ulcerative Colitis), IBS, Acute and Chronic Pancreatitis, Gastrointestinal Malignancies and Familial Cancer Syndromes.
In an effort to share his extensive knowledge with the public, Dr. Sharma released his first book, Pursuit of Gut Happiness: A Guide for Using Probiotics to Achieve Optimal Health, in 2014.
In Dr. Sharma’s free time, he enjoys medical writing, watching movies, exercising and spending time with his family. He believes in “whole person care” and the effect of mind, body and spirit on “wellness”.
ANAND SHUKLA, MS, MBA
With over 20 years of experience in small molecule drug discovery, drug development, and clinical trials, Mr. Shukla brings a wealth of expertise to the company.
Mr. Shukla’s extensive background in drug development, regulatory compliance, and technology transfer makes him a valuable asset. He has a strong track record of successfully filing INDs with the FDA and conducting preclinical and clinical studies, including phase trials.